The corporate venturing unit co-led the vaccine developer's $27.1m series A round with Oxford Sciences Innovation and Sequoia Capital China.
UK-based vaccine developer Vaccitech raised £20m ($27.1m) in a series A round yesterday co-led by GV, the early-stage corporate venturing unit of internet and technology conglomerate Alphabet.
University venturing fund Oxford Sciences Innovation (OSI) and venture capital firm Sequoia Capital China co-led the round with GV, investing alongside Neptune Ventures. Vaccitech is a spinout of University of Oxford.
Founded in 2016, Vaccitech is working on a universal flu vaccine and other vaccine-related products that induce cellular immune responses by relying…
